Q1 2025 Eli Lilly and Co Earnings Call Transcript
Key Points
- Eli Lilly and Co (LLY) reported a 45% increase in revenue compared to Q1 2024, driven by key products such as Mounjaro and Zepbound.
- The company achieved several key pipeline milestones, including the approval of Jaypirca in the EU for CLL and Omvoh in the US, EU, and Japan for Crohn's disease.
- Eli Lilly and Co (LLY) shared promising Phase III clinical data for orforglipron, an oral GLP-1, showing potential for significant impact in Type 2 diabetes and obesity.
- The company announced plans to more than double its US manufacturing investment, with over $50 billion in new investments since 2020.
- Eli Lilly and Co (LLY) distributed $1.3 billion in dividends and executed a $1.2 billion share repurchase in Q1 2025.
- Marketing, selling, and administrative expenses increased by 26%, driven by promotional activities for new launches.
- R&D expenses rose by 8%, primarily due to higher development costs for late-stage assets and early-stage research investments.
- The company recognized acquired IP R&D charges of $1.57 billion, negatively impacting earnings per share by $1.72.
- Eli Lilly and Co (LLY) faces potential challenges from tariffs and trade dynamics, which could negatively affect its financial outlook if expanded.
- The company withdrew its US application for the heart failure with preserved ejection fraction indication for tirzepatide, as the FDA requires an additional confirmatory clinical trial.
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2025 earnings conference call. (Operator Instructions) I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Please go ahead.
Good morning. Thank you for joining us for Eli Lilly company's Q1 2025 Earnings Call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Lucas Montarce, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, President of Lilly Oncology; and Patrik Johnson, President of Cardiometabolic Metabolic Health and Lilly USA.
We're also joined by Mark Keman, Wes Tall and Wai Wong of the Investor Relations team. During this conference call, we anticipate making projections and forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
